Profile data is unavailable for this security.
About the company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
- Revenue in USD (TTM)12.32m
- Net income in USD-175.72m
- Incorporated2007
- Employees181.00
- LocationFate Therapeutics Inc12278 Scripps Summit DriveSAN DIEGO 92131United StatesUSA
- Phone+1 (858) 875-1803
- Fax+1 (302) 636-5454
- Websitehttps://fatetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inozyme Pharma Inc | 0.00 | -88.56m | 324.34m | 59.00 | -- | 3.40 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
AC Immune SA | 18.05m | -70.52m | 334.42m | 133.00 | -- | 2.33 | -- | 18.53 | -0.748 | -0.748 | 0.1949 | 1.45 | 0.0787 | -- | 28.76 | 135,723.90 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
GH Research PLC | -100.00bn | -100.00bn | 337.66m | 49.00 | -- | 1.70 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -69.64m | 339.86m | 164.00 | -- | 1.44 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Climb Bio Inc | 0.00 | -64.20m | 346.03m | 9.00 | -- | 1.55 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 352.79m | 28.00 | -- | 6.89 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 365.95m | 157.00 | -- | 0.5512 | -- | 10.46 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Fate Therapeutics Inc | 12.32m | -175.72m | 366.69m | 181.00 | -- | 0.9235 | -- | 29.77 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
C4 Therapeutics Inc | 29.38m | -107.87m | 373.04m | 145.00 | -- | 1.50 | -- | 12.70 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Biomea Fusion Inc | 0.00 | -139.65m | 379.48m | 112.00 | -- | 3.65 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Voyager Therapeutics Inc | 143.77m | 9.02m | 383.91m | 162.00 | 45.88 | 1.14 | 27.64 | 2.67 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 384.47m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 387.45m | 25.00 | -- | -- | -- | 235.53 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Grail Inc | 109.74m | -2.88bn | 404.57m | 1.37k | -- | 0.1501 | -- | 3.69 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
SAGE Therapeutics Inc | 97.24m | -445.67m | 405.37m | 487.00 | -- | 0.6438 | -- | 4.17 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Organogenesis Holdings Inc | 448.39m | -16.54m | 408.33m | 862.00 | -- | 1.55 | -- | 0.9107 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 07 Jun 2024 | 13.18m | 11.58% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 9.84m | 8.65% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 8.04m | 7.06% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.88m | 6.04% |
Deep Track Capital LPas of 31 Mar 2024 | 5.57m | 4.90% |
Bellevue Asset Management AGas of 31 Mar 2024 | 4.84m | 4.25% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.13m | 2.75% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.82m | 2.48% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 2.73m | 2.40% |
Assenagon Asset Management SA (Germany)as of 30 Jun 2024 | 2.57m | 2.26% |